Physician profile
Robert A Shaffer
NPI 1528002151
$1,032,509.76
in general payments reported to CMS, 2019-2025
37 companies · $248K in 2025
The $248K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134K · 2020: $13K · 2021: $48K · 2022: $92K · 2023: $199K · 2024: $299K · 2025: $248K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $624K · Travel and Lodging: $71K · Food and Beverage: $18K · Consulting Fee: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Honoraria: $3,618 · Education: $63.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $624,110.16 |
| Travel and Lodging | $71,136.82 |
| Food and Beverage | $17,993.14 |
| Consulting Fee | $16,329.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,025.00 |
| Honoraria | $3,618.00 |
| Education | $63.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $339,423.17 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169,902.34 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Phathom Pharmaceuticals, INC. | $162,436.15 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $137,913.10 | 2023-2025 | Dupixent |
| Allergan, INC. | $65,135.10 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $41,846.56 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $40,674.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $39,468.15 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $12,391.56 | 2024-2025 | Iqirvo |
| Abbvie INC. | $6,159.79 | 2019-2025 | Skyrizi, Rinvoq |
| Celltrion USA INC. | $5,491.43 | 2024-2025 | Zymfentra, Vegzelma |
| Eli Lilly and Company | $3,750.00 | 2025 | Omvoh |
| Celgene Corporation | $3,093.32 | 2022-2024 | Zeposia |
| Romark Laboratories, Lc | $1,450.32 | 2019-2020 | |
| Janssen Biotech, INC. | $867.53 | 2021-2025 | Tremfya, Stelara |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $572.57 | 2019-2025 | Entyvio |
| Pfizer INC. | $497.82 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $375.62 | 2019-2025 | |
| Gilead Sciences, INC. | $272.68 | 2019-2025 | |
| Ardelyx, INC. | $135.51 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $123.87 | 2023-2025 | Sucraid, Sucraid |
| Mallinckrodt Hospital Products INC. | $90.39 | 2024 | Terlivaz |
| Evoke Pharma, INC. | $85.23 | 2021-2024 | |
| Braintree Laboratories, INC. | $51.76 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $47.17 | 2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $37.68 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $30.63 | 2019 | |
| Shire North American Group INC | $30.09 | 2019 | |
| Ucb, INC. | $28.20 | 2019 | |
| Orphalan INC | $24.74 | 2024 | Cuvrior |
| Amgen INC. | $19.64 | 2025 | Uplizna |
| Daiichi Sankyo INC. | $18.74 | 2019 | |
| Novo Nordisk INC | $17.66 | 2024 | Ozempic |
| Axonics, INC. | $16.55 | 2024 | Axonics |
| Intra-Sana Laboratories | $15.65 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.82 | 2024 | Rebyota |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.